Prospective Study
Copyright ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 14, 2017; 23(46): 8235-8247
Published online Dec 14, 2017. doi: 10.3748/wjg.v23.i46.8235
Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China
Jin-Min Chen, Tao Liu, Shan Gao, Xu-Dong Tong, Fei-Hong Deng, Biao Nie
Jin-Min Chen, Shan Gao, Xu-Dong Tong, Department of Gastroenterology, Xiangyang Central Hospital, Hubei University of Arts and Science, Xiangyang 441021, Hubei Province, China
Tao Liu, Department of Gastroenterology, the Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou 510665, Guangdong Province, China
Fei-Hong Deng, Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong Province, China
Biao Nie, Department of Gastroenterology, the First Affiliated Hospital of Jinan University, Jinan University, Guangzhou 510630, Guangdong Province, China
Author contributions: Chen JM and Nie B designed the study and wrote the manuscript; Deng FH collected fecal and blood samples and completed patient case report; Liu T and Nie B performed all endoscopies and completed the endoscopic scoring sheet; Tong XD quantified fecal calprotectin; Gao S performed data analysis; all authors read and approved the final manuscript.
Supported by National Natural Science Foundation of China to Biao Nie, No. 81471080.
Institutional review board statement: The study was reviewed and approved by the institutional review board of Department of Gastroenterology in Nanfang Hospital (Guangzhou, China) and the Medical Ethnic Committee of Nanfang Hospital (NFEC-2014-065).
Clinical trial registration statement: The clinical trial was registered in Chinese Clinical Trial Registry (registration ID: ChiCTR-DDT-14005066). Details can be found at http://www.chictr.org.cn/showproj.aspx?proj=4509.
Informed consent statement: All study participants provided written informed consent prior to study enrollment.
Conflict-of-interest statement: The authors of this manuscript have no conflicts of interest to disclose.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at email: niebiao2@163.com. Participants gave informed consent for data sharing.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Biao Nie, MD, PhD, Professor, Associate Chief Physician, Department of Gastroenterology, the First Affiliated Hospital of Jinan University, Jinan University, No. 614, West Huangpu Avenue, Guangzhou 510630, Guangdong Province, China. niebiao2@163.com
Telephone: +86-15101503392 Fax: +86-20-38688025
Received: July 31, 2017
Peer-review started: August 1, 2017
First decision: September 6, 2017
Revised: September 28, 2017
Accepted: November 2, 2017
Article in press: November 2, 2017
Published online: December 14, 2017
Core Tip

Core tip: This was a prospective study conducted in China to assess the efficacy of noninvasive markers, including fecal calprotectin, clinical activity index (CDAI or CAI), CRP, ESR, and procalcitonin (PCT) for monitoring disease activity in colonic or ileo-colonic Crohn’s disease (CICD), CD-related surgery patients, and UC patients and further to optimize the accuracy of those noninvasive biomarkers in detecting active residual mucosal inflammation in IBD patients in clinical remission.